2026 Symposium Vasculitis Foundation
18 May, 2026
Denver, July 17–19 Our colleagues at the Vasculitis Foundation are hosting their 2026 International Vasculitis Symposium in Denver, Colorado from
What’s going on in the world of vasculitis…?
Denver, July 17–19 Our colleagues at the Vasculitis Foundation are hosting their 2026 International Vasculitis Symposium in Denver, Colorado from
Every year on May 15th, the global vasculitis community pauses to be seen. Not just as patients. Not just as
Vasculitis International is pleased to extend its warmest congratulations to the Vasculitis Foundation (VF) on the occasion of its 40th
Vasculitis International has published its position statement on the ongoing regulatory review of TAVNEOS® (avacopan) — and warns that data integrity and risk/benefit analysis are two very different issues and must not be treated as one, when taking action. Otherwise the patient pays for science failure.
The FDA has moved from a review to a formal proposal to withdraw approval of Tavneos in the United States.
This is a more serious step than a review, but it is still not a final decision.
In Europe, the EMA review is still ongoing. No conclusions have been reached yet, and Tavneos is still available.
The U.S. Food and Drug Administration (FDA) issued a Drug Safety
Communication on 31 March 2026, alerting healthcare professionals and patients to serious cases of drug-induced liver injury (DILI) in postmarketing surveillance of avacopan — including cases with fatal outcomes.
While the FDA operates outside the European regulatory framework,
its postmarketing findings are directly relevant to the EMA’s ongoing assessment.